ChromaDex Commences a Clinical Trial on pTeroPure(TM) Pterostilbene
IRVINE, Calif., Sept. 7 /PRNewswire-FirstCall/ — ChromaDex Corporation (OTC Bulletin Board: CDXC), a natural products chemistry company which provides novel and innovative ingredients to the dietary supplement, food, beverage and cosmetic markets, has initiated a clinical study at The University of Mississippi for pTeroPure(TM) pterostilbene (tero-STILL-bean). The next generation, novel ingredient, is based on the grant of an exclusive worldwide license to all patent rights of pterostilbene from the University of Mississippi.
Pterostilbene is chemically related to resveratrol, a compound that can be found in grapes, blueberries, and other small fruits, as well as the bark of some trees. In laboratory tests, pterostilbene has shown promise for improving cardiovascular health, glucose levels, anti-ageing and cognitive function; and, for possessing cancer-fighting properties. Various scientific publications have shown that pterostilbene has significantly higher activity than resveratrol.
The clinical trial is being conducted at the UM Medical Center in Jackson, where investigators hope to evaluate the compound in patients with lipid (cholesterol) disorders. Patients enrolled in the study will receive high and low doses of pterostilbene -with and without grape extract, or a placebo, said Daniel Riche, assistant professor of pharmacy practice and medicine, and the study’s principal investigator.
“We are excited to be collaborating with ChromaDex on the first clinical investigation for pterostilbene,” Dr. Riche said. “Pterostilbene has significant promise, and we hope it will offer a useful non-prescription option for metabolic disorders. In addition to cholesterol and blood pressure, we will be evaluating urine tests and monitoring for inflammatory markers,” said Riche. “Reductions in these markers may correlate with improvements in oxidative stress.”
Assisting Riche with the study are Justin J. Sherman, associate professor of pharmacy practice, and Dr. C. Andrew Brown, professor of medicine at the UM Medical Center in Jackson.
“The commencement of our pTeroPure pterostilbene clinical study with the University of Mississippi marks another significant milestone for ChromaDex,” said Frank Jaksch, CEO and co-founder of ChromaDex. “Most people may not yet know of pterostilbene, but we believe this naturally occurring compound’s improved activity and potency may soon make it as well known as its highly-successful, well known relative, resveratrol.”
References to publications and white papers on the potential benefits of pterostilbene can be found at http://www.chromadex.com/Literature/Brochures/PterostilbeneBrochure.pdf
ChromaDex (http://www.chromadex.com/) is a leader in the development of Phytochemical and Botanical Reference Standards and the creation of associated intellectual property. ChromaDex is committed to sustainable “Green chemistry” and provides the dietary supplement, food, beverage, nutraceutical and cosmetic industries with the novel ingredients, analytical tools and services to meet product regulatory, quality, efficacy and safety standards. Among other things, the Company is currently focusing on clinical studies and the commercialization of its new product, pTeroPure(TM) pterostilbene (http://www.pteropure.com/) as a result of its exclusive worldwide patent rights for pterostilbene. Corporate address: 10005 Muirlands Blvd; Suite G; Irvine, CA 92618
Any statements that are not historical facts contained in this release are forward-looking statements. Actual results may differ materially from those projected or implied in any forward-looking statements. Such statements involve risks and uncertainties, including but not limited to: the ability to market, produce and sell the referenced ingredients; risks relating to product and customer demand, market acceptance of our products; the effect of economic conditions both nationally and internationally; the ability to protect our intellectual property rights; the impact of any litigation or infringement actions brought against us; competition from other providers and products; risks in product development; our ability to raise capital to fund continuing operations; the ability to complete transactions; and other factors discussed from time to time in the Company’s Securities and Exchange Commission filings. The Company undertakes no obligation to update or revise any forward-looking statement for events or circumstances after the date on which such statement is made except as required by law.
Investor Inquiries: Liviakis Financial Communications, Inc. John M. Liviakis, President 415-389-4670 John@Liviakis.com Media Inquiries: Megan Lavine Canale Communications 619-849-5388 Megan@canalecomm.com
SOURCE ChromaDex Corporation